Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multi-centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel or Cabazitaxel.

NCT02362620 is registered in ClinicalTrials.gov with Centro Nacional de Investigaciones Oncologicas CARLOS III as lead sponsor.

NCT NCT02362620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02362620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multi-centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel or Cabazitaxel.
Lead sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase
Observational
Overall status
Unknown status
Start date
May 31, 2014
Completion date
December 31, 2020
Enrollment
402 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer, cabazitaxel, docetaxel